Kyoko Watanabe

Actuate Therapeutics, Inc. is a pharmaceuticals company based out of 1401 FOCH ST, Fort Worth, Texas, United States.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

InformAI develops AI-enabled healthcare diagnostic-assist tools and patient outcome predictors for leading healthcare systems and national physician groups. Our AI software enables faster patient diagnoses at the point of care and improved patient outcome risk analysis.

DiA Imaging Analysis is a leading global provider of FDA-cleared and CE-marked ultrasound AI software that automates how clinicians use and analyze ultrasound images. The companys LVivo product line for cardiac and abdominal automated analysis allows clinicians with varying levels of ultrasound experience to automatically analyze ultrasound images increasing speed, efficiency, and accuracy. Our AI-based cardiac ultrasound analysis software LVivo Seamless™ runs behind-the-scenes, automatically selecting and analyzing the optimal apical views, then generating reproducible and accurate key measurements including Strain, EF and RV size and function on every echo exam. Today, DiA serves thousands of end-users worldwide. DiA was recognized as one of Fast Companys 2022 World Changing Ideas in the Health Category and was recently named as one of CB Insights most innovative digital health startups. Dia was acquired by Philips in 2023

Savonix is the only digital neuropsychology platform in the market. We empower patients, providers, payers, and researchers with cognitive solutions to fight against dementia. Clinically validated, our cloud-based platform allows users to screen for cognitive health directly from their mobile device. Privacy Statement: https://savonix.com/terms-and-privacy/ For a demonstration of the cognitive solutions we offer: https://savonix.com/contact/

Actuate Therapeutics, Inc. is a pharmaceuticals company based out of 1401 FOCH ST, Fort Worth, Texas, United States.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

InformAI develops AI-enabled healthcare diagnostic-assist tools and patient outcome predictors for leading healthcare systems and national physician groups. Our AI software enables faster patient diagnoses at the point of care and improved patient outcome risk analysis.

DiA Imaging Analysis is a leading global provider of FDA-cleared and CE-marked ultrasound AI software that automates how clinicians use and analyze ultrasound images. The companys LVivo product line for cardiac and abdominal automated analysis allows clinicians with varying levels of ultrasound experience to automatically analyze ultrasound images increasing speed, efficiency, and accuracy. Our AI-based cardiac ultrasound analysis software LVivo Seamless™ runs behind-the-scenes, automatically selecting and analyzing the optimal apical views, then generating reproducible and accurate key measurements including Strain, EF and RV size and function on every echo exam. Today, DiA serves thousands of end-users worldwide. DiA was recognized as one of Fast Companys 2022 World Changing Ideas in the Health Category and was recently named as one of CB Insights most innovative digital health startups. Dia was acquired by Philips in 2023